Electroconvulsive shock (ECS) is a highly effective therapy for the treatment of major depression, but its mechanisms of action are not known. We report that repeated ECS in rats produces enduring changes in two clinically relevant stress-responsive brain systems: (a) the hypothalamic-pituitary-adrenal axis regulated by corticotropin-releasing hormone (CRH) in the paraventricular nucleus; and (b) the NE system in the locus coeruleus regulated by tyrosine hydroxylase (TH). CRH and TH mRNA levels in these brain regions were assessed by in situ hybridization histochemistry. A single interaural ECS elevated TH but not CRH mRNA measured 24 h later. Repeated daily treatments (3, 7, or 14) elevated both mRNAs, maximally with 7, correlating with the time course of clinical efficacy. The elevations persisted for 3 (CRH) or 8 wk (TH) after the ECS. No other therapeutic treatment is known to produce such longlasting changes in central nervous system gene expression. The time course of events (delayed onset, long duration) implicate CRH as a principal mediator of the antidepressant effects of ECS. The locus coeruleus-NE system may be important in initiating the central nervous system response. (J. Clin. Invest. 1994.94:1263-1268
Introduction
Electroconvulsive shock (ECS)1 is one of the most clinically effective therapies available for the treatment of major depression, and is used primarily in severe cases that do not respond to antidepressant drugs (1) (2) (3) . The treatment consists of repeated administration of electroconvulsive shock (usually 6-12 treat-ments, 3 per wk) over a 1-2-wk period, after which the patients show a dramatic improvement that persists for months (2, 3) . Despite its well-documented therapeutic efficacy, the mechanism(s) of action underlying the antidepressant effects of ECS is not known.
In this study, the effects of acute and repeated ECS treatment in rats are examined to define the persistent central nervous system (CNS) changes that might underlie the therapeutic efficacy of ECS in depression. We have focused on two major CNS systems, namely (a) the hypothalamic-pituitary-adrenal (HPA) axis regulated by the stress-responsive hormone corticotropin-releasing hormone (CRH) in the hypothalamic paraventricular nucleus (PVN), and (b) the NE system in the locus coeruleus (LC) which is regulated by tyrosine hydroxylase (TH), the rate-limiting enzyme in NE biosynthesis, because they are thought to be dysregulated in major depression in humans (4) . Moreover, we have shown that these systems are selectively altered by stress (5) and antidepressant drug treatment (6, 7).
Methods
Animals. Male Sprague-Dawley rats (175-200 g; Taconic Farms Inc., Germantown, NY) were housed three to a cage at 24'C with lights on from 0600 to 1800 h. The animal procedures used in these studies were in strict accordance with the National Institutes of Health Guide for the Care and Use ofLaboratory Animals and were approved by the National Institute of Mental Health Animal Care and Use Committee. ECS treatment. ECS was administered to the rats by the application of an 80-mA current via ear-clip electrodes for a duration of 0.5 s using an ECS device (Annett's Industries, Oxford, United Kingdom). ECStreated rats immediately exhibited generalized tonic-clonic convulsions which lasted 20-30 s. Control animals were treated similarly but received 0 mA current. Animals were killed 24 h after the last treatment.
To determine the optimal treatment-effect relationship of ECS on mRNA levels in brain, groups of animals were administered ECS daily for 1, 3, 7, or 14 d. After the optimal number of treatments was determined, additional groups of rats were administered ECS in a temporal regimen similar to that used clinically: three times a week (Monday, Wednesday, and Friday) for a total of seven treatments.
To determine the duration of the effects of repeated ECS on mRNA levels in brain, groups of rats were administered ECS daily for 7 d (the optimal number of treatments determined in the previous study) and were killed 24 h, 3 Pentylenetetrazole produced tonic-clonic seizures in all animals within 1-2 min after injection. Rats were killed 24 h after the last injection.
Electroconvulsive Shock Alters CRH and TH mRNA Levels in Rat BrainTissue and plasma collection. Animals were transported singly from the housing room to a treatment room (transport time < 3 min) and killed by decapitation between 1000 and 1200 h. Brains were removed, frozen by immersion in 2-methyl butane at -300C, and stored at -700C before sectioning. Adrenal glands were removed, dissected on ice, and weighed. Trunk blood was collected on ice in tubes containing EDTA, centrifuged (3,000 rpm for 20 min at 40C), and the plasma was frozen at -700C. Plasma ACTH and corticosterone levels were measured by RIA kits (ICN Biochemicals, Cleveland, OH). The interassay coefficient of variance was < 10%.
In situ hybridization histochemistry. Frozen sections (15 pm thick) were cut coronally through the midportion of the parvocellular region of the PVN (-1.8 mm relative to bregma), dorsal hippocampus (-3.3 mm relative to bregma), pituitary, and LC (-9.7 mm relative to bregma) (8 (Table I) . Repeated ECS (3, 7, or 14 daily treatments) produced large elevations in mRNA levels of peptides and biosynthetic enzymes in brain 24 h after the end of treatment. TH mRNA levels in the LC were markedly increased by ECS with a peak effect seen after seven treatments (367% of control) (Fig. 1) . CRH mRNA levels in the PVN rose to their peak after three treatments (210% of control) and then plateaued (Fig. 1) . POMC mRNA levels in the anterior pituitary were significantly increased after 3 and 7 ECS treatments (19-27% increase, P < 0.05) and no longer differed from control levels by 14 treatments. MR mRNA levels in the hippocampus were not altered by repeated ECS treatment.
Repeated daily ECS administration elevated plasma ACTH and corticosterone levels, reaching peak effects, a 27-fold increase in ACTH and a 3-fold increase in corticosterone, after 7 treatments (Table I) . At this time point, adrenal gland weight was increased by 81%, and body weight was reduced by 13% (Table I) . After 14 ECS treatments, elevations in ACTH and corticosterone levels were smaller in magnitude, and no effect was seen on adrenal gland weight. Body weight, however, continued to be reduced by 15% at this time point (Table I) .
Effects induced by seven ECS treatments administered three times per week. After the optimal number of ECS treatments was determined to be seven, ECS was administered three times per week for a total of seven treatments in order to mimic the (Table I , Fig. 1 ). No increase in POMC mRNA levels was seen in the anterior pituitary (Table I) . Plasma ACTH levels were elevated to the same extent as after seven daily ECS treatments, whereas plasma corticosterone levels and adrenal gland weight did not differ from control (Table I) . Body weight was reduced by 20% with this ECS regimen ( Table I) . Persistence of the effects induced by seven daily ECS treatments. Because seven daily ECS treatments produced a peak increase in TH mRNA levels in the LC and CRH mRNA levels in the PVN, this number of treatments was chosen to examine the persistence of ECS-induced changes in mRNA levels in brain. 3 wk after discontinuation of ECS, TH mRNA levels in the LC continued to be elevated, but to a lesser degree ( 133±8% of control), (Figs. 2 and 3,c and d ). 8 the increased TH mRNA levels in the LC persisted with no further decrement. CRH mRNA levels in the PVN were elevated without a decrement in effect (202±13% of control) 3 wk after discontinuation of ECS (Figs. 2 and 4 
c). The increase in CRH message was no longer evident after 8 wk (Figs. 2 and 4 c).
No alterations in POMC mRNA levels in the anterior pituitary or in plasma levels of ACTH and corticosterone were evident 3 wk after repeated ECS treatment. Adrenal gland weight and body weight did not differ from control 3 wk after ECS treatment.
Effects of pentylenetetrazole-induced seizures on brain mRNA. Pentylenetetrazole (PTZ) administration was used as a model of generalized tonic-clonic convulsions to determine if ECS-induced changes in mRNA levels could be reproduced by the induction of generalized seizures or if the effects were specific to ECS treatment. Acute administration of PTZ (35 mg/ kg, i.p.) produced tonic-clonic seizures in all animals. These seizures were longer in duration than those induced by ECS. PTZ increased CRH mRNA levels in the PVN (159±9% of control, P < 0.05) and elevated plasma levels of ACTH and corticosterone 24 h after treatment (Table I) . Repeated PTZ administration for 3 d elevated plasma levels of ACTH and corticosterone (Table I) , but did not significantly alter CRH mRNA levels in the PVN 24 h after the last injection.
Discussion
A single exposure to ECS increased TH mRNA levels in the LC and decreased MR mRNA levels in the hippocampal CA fields and dentate gyrus. These changes were accompanied by an increase in plasma levels of ACTH. The effects were measured 24 h after ECS and thus reflect the profile of CNS changes induced by the ECS treatment rather than the immediate effects produced by the seizure itself.
The increase in TH mRNA levels in the LC after a single ECS may be an adaptive compensatory response to the ECSinduced increase in utilization of NE in terminal regions in brain. As a consequence of a single ECS, NE synthesis is stimulated in the LC and its terminal fields (14) and a rapid, shortlasting increase in TH enzyme activity is induced ( 15, 16 increase in TH mRNA levels, a twofold increase in the LC measured 24 h after ECS, is much larger in magnitude and longer in duration than thiat produced by acute stress (5, 17, 18) or reserpine admninistration (19) , treatments which stimulate NE
turnover. An immediate and transient increase in corticosterone levels has been reported previously 10-30 min after a single ECS, followed by a return to baseline by 1 h (20) . The temporary decrease in hippocampal MR mRNA levels seen 24 h after a single ECS may be an acute compensatory response to eleva-tions in corticosterone which may serve to reduce negative feedback onto the PVN (21) . Plasma levels of ACTH were elevated 24 h after one, three, or seven (three times per week) ECS treatments, whereas corticosterone levels were unaltered. The dissociation in plasma measures could be the result of transporting animals from the housing room to the treatment room (transport time < 3 min) before killing, if the stress of ECS treatment 24 h earlier resulted in facilitation of ACTH release in the treated rats.
Elevations in mRNA levels of stress-responsive elements in the hypothalamic and pituitary components of the HPA axis, CRH in the PVN and POMC in the anterior pituitary, were not evident after a single ECS. Instead, multiple ECS treatments were required to increase these message levels. Maximal activation of the HPA axis (peak increases in PVN CRH mRNA levels, plasma ACTH and corticosterone levels, and adrenal gland weight) and maximal activation of the LC-NE system were seen after seven daily ECS treatments. Additional treatment for 14 d did not further increase mRNA levels.
Multiple ECS treatments did not alter the mRNA levels of MR or GR in the hippocampus despite the presence of large and persistent elevations in plasma ACTH and corticosterone. We have shown previously that hippocampal MR message is altered after acute but not chronic stress (5) . The hippocampus may be more sensitive to acute episodic variations in corticosterone than it is to chronically elevated levels.
To reproduce the temporal regimen of ECS treatments used clinically, ECS was administered three times per week for a total of seven treatments. The effects of this treatment were qualitatively similar to those produced by seven consecutive ECS administrations. However, the ECS-induced increases in mRNA levels of TH in the LC and CRH in the PVN were less in magnitude, and no adrenal gland hypertrophy or loss of body weight was apparent. Thus, the frequency (temporal spacing) of ECS treatments is important in determining the degree of activation of the HPA axis and LC-NE system.
It is not unexpected that ECS treatment altered the activity of the hypothalamic CRH and LC-NE systems, since these systems are key components of the CNS regulatory mechanisms responding to stress (18) . The effects of repeated ECS on mRNA levels of TH in the LC and CRH in the PVN are greater in magnitude and duration than the effects of repeated stress on these messages (5, 17, 22) , suggesting that in rats ECS may be the most potent available stressor.
To elucidate the neurochemical mechanisms responsible for the therapeutic effects of ECS, or of any antidepressant agent, it is important to establish that (a) the therapeutic effects appear only after multiple treatments, and (b) that these effects persist for an extended period of time after the termination of treatment. In this study, we have identified two CNS systems, hypothalamic CRH and the LC-NE system, that satisfy these criteria. The evidence is as follows. First, CRH mRNA levels in the PVN are increased after repeated ECS treatments but not after a single ECS. Second, hypothalamic CRH and the LC-NE system are maximally activated after repeated daily ECS treatments. Third, the number of treatments producing maximal activation of the HPA axis and LC-NE system (seven) lies within the range of therapeutic efficacy of ECS in treating depression (1) (2) (3) 16) . These two systems are also activated when ECS treatment is administered three times per week in a temporal regimen similar to that used clinically. Finally, repeated ECS treatments produce marked and enduring elevations in mRNA levels of CRH in the PVN (3 wk) and TH in the LC (8 wk) (Fig. 2) . The therapeutic effects of ECS dissipate within 2-3 mo after ECS treatment, and maintenance electroconvulsive therapy or antidepressant drug administration must be initiated within this time period to prevent a relapse of depression (1-3, 16, 23, 24) . Collectively, the temporal aspects of the CRH effect in this study indicate that hypothalamic CRH plays a key role in the antidepressant effects of ECS. The immediate and prolonged activation of the LC-NE system by ECS may be important in initiating and maintaining the response of hypothalamic CRH to ECS.
We reported previously that repeated administration of antidepressant drugs decreases mRNA levels of CRH in the PVN (6, 7). We suggested that the CRH effect is relevant to the therapeutic efficacy of antidepressant drugs in depression because (a) the temporal aspects of the effect agree with the delayed onset of therapeutic efficacy, and (b) the direction of the effect is opposite and may therefore counteract the hypersecretion of CRH found in major depression (4, (25) (26) (27) (28) (29) .
In this study, we show that ECS treatment differs from that of antidepressant drugs by increasing rather than decreasing levels of CRH mRNA. Further studies of the effects of ECS treatment on mRNA levels in stressed animals or in animal models of depression will reveal more about the mechanism of action of ECS and the role of hypothalamic CRH. At this point in our studies, the increases in PVN CRH message and LC TH message by ECS suggest that elevated levels per se of CRH and NE observed in depression and in animal models of chronic stress are not causal factors for these conditions.
Two hypotheses of the antidepressant efficacy of ECS have been proposed. The receptor hypothesis emphasizes alterations in neurotransmitter receptors as the primary mechanism of action of ECS in affective disorders (30) (31) (32) (33) . This hypothesis invokes common mechanisms in mediating the therapeutic effects of ECS and antidepressant drugs but does not account for the finding that some depressed patients respond to ECS but not to drugs (34) . The neuropeptide hypothesis suggests that dysregulation of hypothalamic peptides underlies the pathogenesis of affective disorders (4, 25, (35) (36) (37) . In depressed patients who respond to a course of ECS treatment, ECS alters neuroendocrine secretion of CRH, fi-endorphin, growth hormone, prolactin, and somatostatin (36, (38) (39) (40) (41) . Our findings suggest a merger of the two hypotheses: the antidepressant effects of ECS are mediated by an initial activation of neurotransmitter systems including the LC-NE system followed by a delayed activation of hypothalamic neuropeptide systems, primarily CRH.
In summary, repeated ECS produces marked and enduring elevations in mRNA levels of TH in the LC and CRH in the PVN. No other therapeutic drug or treatment is known to produce such persistent changes in CNS gene expression. We suggest that the ability of ECS to resolve depressions which are not responsive to antidepressant drug treatment may be related to its unique ability to produce a long-lasting activation of the hypothalamic CRH and LC-NE systems.
